Do analysts prefer OCS or NNNN?

Oculis presently has a consensus target price of $38.33, suggesting a potential upside of 245.66%. Given Oculis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Oculis is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, OCS or NNNN?

Anbio Biotechnology has higher revenue and earnings than Oculis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 443.45 -$119.44M -$2.13 N/A Anbio Biotechnology $8.65M 259.43 $6.40M N/A N/A

Which has stronger valuation & earnings, OCS or ALMS?

Oculis has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 443.45 -$119.44M -$2.13 N/A Alumis $8.40M 366.45 -$243.32M -$1.98 N/A

Is OCS or ALMS more profitable?

Alumis has a net margin of -2,825.70% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Alumis -2,825.70% -88.79% -70.72%

Does the media refer more to OCS or ALMS?

In the previous week, Oculis had 11 more articles in the media than Alumis. MarketBeat recorded 14 mentions for Oculis and 3 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Oculis' score of 0.53 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OCS or VERA more profitable?

Vera Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Vera Therapeutics N/A -74.86% -60.18%

Does the media refer more to OCS or VERA?

In the previous week, Oculis had 9 more articles in the media than Vera Therapeutics. MarketBeat recorded 14 mentions for Oculis and 5 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.75 beat Oculis' score of 0.53 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OCS or RARE?

In the previous week, Oculis had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 14 mentions for Oculis and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.19 beat Oculis' score of 0.53 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OCS or ELVN?

In the previous week, Enliven Therapeutics had 5 more articles in the media than Oculis. MarketBeat recorded 19 mentions for Enliven Therapeutics and 14 mentions for Oculis. Oculis' average media sentiment score of 0.53 beat Enliven Therapeutics' score of 0.29 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Oculis (OCS) Competitors

$11.09 +0.09 (+0.82%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$11.33 +0.24 (+2.16%)

As of 06/12/2026 07:32 PM Eastern

Compare

OCS vs. NNNN, ALMS, VERA, RARE, and ELVN

Should you buy Oculis stock or one of its competitors? MarketBeat compares Oculis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oculis include Anbio Biotechnology (NNNN), Alumis (ALMS), Vera Therapeutics (VERA), Ultragenyx Pharmaceutical (RARE), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry.

How does Oculis compare to Anbio Biotechnology?

Oculis (NASDAQ:OCS) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Anbio Biotechnology has higher revenue and earnings than Oculis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	443.45	-$119.44M	-$2.13	N/A
Anbio Biotechnology	$8.65M	259.43	$6.40M	N/A	N/A

Oculis has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, indicating that its share price is 338% more volatile than the broader market.

Anbio Biotechnology has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Anbio Biotechnology's return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Anbio Biotechnology	N/A	N/A	N/A

In the previous week, Oculis had 13 more articles in the media than Anbio Biotechnology. MarketBeat recorded 14 mentions for Oculis and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.89 beat Oculis' score of 0.53 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Oculis	Positive
Anbio Biotechnology	Very Positive

Oculis presently has a consensus target price of $38.33, suggesting a potential upside of 245.66%. Given Oculis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Oculis is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

22.3% of Oculis shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Anbio Biotechnology beats Oculis on 7 of the 13 factors compared between the two stocks.

How does Oculis compare to Alumis?

Oculis (NASDAQ:OCS) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Oculis has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	443.45	-$119.44M	-$2.13	N/A
Alumis	$8.40M	366.45	-$243.32M	-$1.98	N/A

Oculis presently has a consensus price target of $38.33, suggesting a potential upside of 245.66%. Alumis has a consensus price target of $40.30, suggesting a potential upside of 66.87%. Given Oculis' higher possible upside, analysts plainly believe Oculis is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Oculis has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Alumis has a beta of -0.56, meaning that its share price is 156% less volatile than the broader market.

22.3% of Oculis shares are owned by institutional investors. 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alumis has a net margin of -2,825.70% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Alumis	-2,825.70%	-88.79%	-70.72%

In the previous week, Oculis had 11 more articles in the media than Alumis. MarketBeat recorded 14 mentions for Oculis and 3 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Oculis' score of 0.53 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oculis beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Oculis compare to Vera Therapeutics?

Oculis (NASDAQ:OCS) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Oculis has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	443.45	-$119.44M	-$2.13	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Vera Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Vera Therapeutics	N/A	-74.86%	-60.18%

In the previous week, Oculis had 9 more articles in the media than Vera Therapeutics. MarketBeat recorded 14 mentions for Oculis and 5 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.75 beat Oculis' score of 0.53 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oculis currently has a consensus target price of $38.33, suggesting a potential upside of 245.66%. Vera Therapeutics has a consensus target price of $78.00, suggesting a potential upside of 127.67%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Oculis has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

22.3% of Oculis shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Oculis beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Oculis compare to Ultragenyx Pharmaceutical?

Oculis (NASDAQ:OCS) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

22.3% of Oculis shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oculis has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Oculis presently has a consensus price target of $38.33, indicating a potential upside of 245.66%. Ultragenyx Pharmaceutical has a consensus price target of $59.56, indicating a potential upside of 144.61%. Given Oculis' higher possible upside, research analysts clearly believe Oculis is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Oculis had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 14 mentions for Oculis and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.19 beat Oculis' score of 0.53 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oculis has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Oculis is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	443.45	-$119.44M	-$2.13	N/A
Ultragenyx Pharmaceutical	$670M	3.58	-$575M	-$6.11	N/A

Summary

Ultragenyx Pharmaceutical beats Oculis on 10 of the 17 factors compared between the two stocks.

How does Oculis compare to Enliven Therapeutics?

Oculis (NASDAQ:OCS) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

22.3% of Oculis shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Enliven Therapeutics has lower revenue, but higher earnings than Oculis. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	443.45	-$119.44M	-$2.13	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Oculis has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Enliven Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Enliven Therapeutics' return on equity of -21.04% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Enliven Therapeutics	N/A	-21.04%	-20.41%

In the previous week, Enliven Therapeutics had 5 more articles in the media than Oculis. MarketBeat recorded 19 mentions for Enliven Therapeutics and 14 mentions for Oculis. Oculis' average media sentiment score of 0.53 beat Enliven Therapeutics' score of 0.29 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oculis currently has a consensus price target of $38.33, suggesting a potential upside of 245.66%. Enliven Therapeutics has a consensus price target of $61.50, suggesting a potential upside of 33.32%. Given Oculis' higher possible upside, equities analysts plainly believe Oculis is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Enliven Therapeutics beats Oculis on 11 of the 16 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCS vs. The Competition

Export

Metric	Oculis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$643.04M	$3.40B	$6.73B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-5.21	19.82	24.24	24.42
Price / Sales	443.45	181.03	483.22	88.50
Price / Cash	N/A	123.04	43.54	55.64
Price / Book	2.72	8.32	10.65	6.80
Net Income	-$119.44M	$23.94M	$3.57B	$338.00M
7 Day Performance	-1.07%	3.53%	0.84%	2.68%
1 Month Performance	-63.30%	-2.55%	-0.34%	1.56%
1 Year Performance	-41.69%	44.82%	25.40%	30.59%

Oculis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCS Oculis	3.4659 of 5 stars	$11.09 +0.8%	$38.33 +245.7%	-41.7%	$643.04M	$1.45M	N/A	2	Analyst Forecast Gap Up
NNNN Anbio Biotechnology	1.5374 of 5 stars	$17.00 -1.3%	N/A	N/A	$2.45B	$8.65M	N/A	27	Positive News
ALMS Alumis	3.0709 of 5 stars	$19.15 +0.9%	$40.30 +110.4%	+669.1%	$2.44B	$24.05M	N/A	N/A
VERA Vera Therapeutics	2.8671 of 5 stars	$31.77 +0.1%	$78.00 +145.5%	+50.7%	$2.28B	N/A	N/A	40
RARE Ultragenyx Pharmaceutical	3.2092 of 5 stars	$22.85 +5.8%	$59.56 +160.7%	-35.0%	$2.25B	$673M	N/A	1,371

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCS) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oculis (OCS) Competitors

OCS vs. NNNN, ALMS, VERA, RARE, and ELVN

How does Oculis compare to Anbio Biotechnology?

Summary

How does Oculis compare to Alumis?

Summary

How does Oculis compare to Vera Therapeutics?

Summary

How does Oculis compare to Ultragenyx Pharmaceutical?

Summary

How does Oculis compare to Enliven Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oculis (OCS) Competitors

OCS vs. NNNN, ALMS, VERA, RARE, and ELVN

How does Oculis compare to Anbio Biotechnology?

Which has higher valuation & earnings, OCS or NNNN?

Which has more volatility & risk, OCS or NNNN?

Is OCS or NNNN more profitable?

Does the media favor OCS or NNNN?

Do analysts prefer OCS or NNNN?

Do insiders and institutionals have more ownership in OCS or NNNN?

Summary

How does Oculis compare to Alumis?

Which has stronger valuation & earnings, OCS or ALMS?

Do analysts rate OCS or ALMS?

Which has more risk & volatility, OCS or ALMS?

Do institutionals & insiders hold more shares of OCS or ALMS?

Is OCS or ALMS more profitable?

Does the media refer more to OCS or ALMS?

Summary

How does Oculis compare to Vera Therapeutics?

Which has stronger earnings & valuation, OCS or VERA?

Is OCS or VERA more profitable?

Does the media refer more to OCS or VERA?

Do analysts prefer OCS or VERA?

Which has more risk & volatility, OCS or VERA?

Do institutionals and insiders have more ownership in OCS or VERA?

Summary

How does Oculis compare to Ultragenyx Pharmaceutical?

Do insiders and institutionals believe in OCS or RARE?

Which has more risk and volatility, OCS or RARE?

Do analysts recommend OCS or RARE?

Is OCS or RARE more profitable?

Does the media favor OCS or RARE?

Which has stronger earnings & valuation, OCS or RARE?

Summary

How does Oculis compare to Enliven Therapeutics?

Do insiders & institutionals hold more shares of OCS or ELVN?

Which has preferable earnings and valuation, OCS or ELVN?

Which has more risk and volatility, OCS or ELVN?

Is OCS or ELVN more profitable?

Does the media refer more to OCS or ELVN?

Do analysts prefer OCS or ELVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools